TCR2 Therapeutics Inc logo

TCRR - TCR2 Therapeutics Inc Share Price

$15.55 -0.6  -3.4%

Last Trade - 02/07/20

Sector
Healthcare
Size
Small Cap
Market Cap £299.9m
Enterprise Value £198.9m
Revenue £n/a
Position in Universe 3131st / 6344
Bullish
Bearish
Unlock TCRR Revenue
Momentum
Relative Strength (%)
1m +33.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Tcr2 Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 74% to $15.5M. Lower net loss reflects Research and development - Balancing va decrease of 27% to $5.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.50 to -$0.65.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

TCRR Revenue Unlock TCRR Revenue

Net Income

TCRR Net Income Unlock TCRR Revenue

Normalised EPS

TCRR Normalised EPS Unlock TCRR Revenue

PE Ratio Range

TCRR PE Ratio Range Unlock TCRR Revenue

Dividend Yield Range

TCRR Dividend Yield Range Unlock TCRR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TCRR EPS Forecasts Unlock TCRR Revenue
Profile Summary

TCR2 Therapeutics, Inc. is an immunotherapy company, which is developing novel T cell therapies for patients suffering from cancer. The Company’s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The Company has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across various tumor targets. The Company has also developed combinations of TRuC variants with elements designed to sustain the immunotherapeutic response and counteract the immunosuppressive tumor microenvironment. Its platform is highlighted with multiple programs of product candidate, which include TC-210, TC-220, TC-410, TC-110 and TC-310.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated May 29, 2015
Public Since February 14, 2019
No. of Shareholders: 19
No. of Employees: 87
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 24,075,917
Free Float (0.0%)
Eligible for
ISAs
SIPPs
TCRR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for TCRR
Upcoming Events for TCRR
Frequently Asked Questions for TCR2 Therapeutics Inc
What is the TCR2 Therapeutics Inc share price?

As of 02/07/20, shares in TCR2 Therapeutics Inc are trading at $15.55, giving the company a market capitalisation of £299.9m. This share price information is delayed by 15 minutes.

How has the TCR2 Therapeutics Inc share price performed this year?

Shares in TCR2 Therapeutics Inc are currently trading at $15.55 and the price has moved by 12.68% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the TCR2 Therapeutics Inc price has moved by 7.66% over the past year.

What are the analyst and broker recommendations for TCR2 Therapeutics Inc?

Of the analysts with advisory recommendations for TCR2 Therapeutics Inc, there are there are currently 3 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for TCR2 Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will TCR2 Therapeutics Inc next release its financial results?

TCR2 Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the TCR2 Therapeutics Inc dividend yield?

TCR2 Therapeutics Inc does not currently pay a dividend.

Does TCR2 Therapeutics Inc pay a dividend?

TCR2 Therapeutics Inc does not currently pay a dividend.

When does TCR2 Therapeutics Inc next pay dividends?

TCR2 Therapeutics Inc does not currently pay a dividend.

How do I buy TCR2 Therapeutics Inc shares?

To buy shares in TCR2 Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of TCR2 Therapeutics Inc?

Shares in TCR2 Therapeutics Inc are currently trading at $15.55, giving the company a market capitalisation of £299.9m.

Where are TCR2 Therapeutics Inc shares listed? Where are TCR2 Therapeutics Inc shares listed?

Here are the trading details for TCR2 Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: TCRR
What kind of share is TCR2 Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, TCR2 Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a TCR2 Therapeutics Inc share price forecast 2020?

Shares in TCR2 Therapeutics Inc are currently priced at $15.55. At that level they are trading at 58.65% discount to the analyst consensus target price of 0.00.

Analysts covering TCR2 Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.587 for the next financial year.

How can I tell whether the TCR2 Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TCR2 Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 17.46%. At the current price of $15.55, shares in TCR2 Therapeutics Inc are trading at 17.08% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the TCR2 Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for TCR2 Therapeutics Inc.

Who are the key directors of TCR2 Therapeutics Inc?

TCR2 Therapeutics Inc's management team is headed by:

Ansbert Gadicke - CHM
Ian Somaiya - CFO
Garry Menzel - PRE
Robert Hofmeister - CSO
Stephen Turkowiak - VFN
Andrew Cornforth - VPR
Alfonso Cardama - OTH
Axel Hoos - DRC
Stephen Webster - IND
Who are the major shareholders of TCR2 Therapeutics Inc?

Here are the top five shareholders of TCR2 Therapeutics Inc based on the size of their shareholding:

MPM Capital Inc. Investment Advisor/Hedge Fund
Percentage owned: 16.83% (4.05m shares)
MPM Oncology Impact Management LP Investment Advisor/Hedge Fund
Percentage owned: 14% (3.37m shares)
F2 Capital Ltd Private Equity
Percentage owned: 9.29% (2.24m shares)
Cathay Fortune Corp. Private Equity
Percentage owned: 8.88% (2.14m shares)
Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 7.34% (1.77m shares)
Similar to TCRR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.